S&P 500   3,954.71 (+0.53%)
DOW   33,699.14 (+0.30%)
QQQ   283.31 (+0.99%)
AAPL   142.20 (+0.89%)
MSFT   247.27 (+1.19%)
META   115.55 (+1.42%)
GOOGL   94.20 (-0.78%)
AMZN   89.77 (+1.48%)
TSLA   172.03 (-1.15%)
NVDA   168.84 (+4.74%)
NIO   13.37 (+6.28%)
BABA   94.11 (+6.54%)
AMD   69.76 (-0.54%)
T   19.19 (-0.57%)
MU   55.24 (+2.64%)
CGC   3.05 (-5.86%)
F   13.11 (+0.08%)
GE   83.38 (-1.91%)
DIS   92.51 (+0.39%)
AMC   6.12 (+1.16%)
PYPL   74.44 (+0.03%)
PFE   51.66 (+2.83%)
NFLX   308.73 (+0.10%)
S&P 500   3,954.71 (+0.53%)
DOW   33,699.14 (+0.30%)
QQQ   283.31 (+0.99%)
AAPL   142.20 (+0.89%)
MSFT   247.27 (+1.19%)
META   115.55 (+1.42%)
GOOGL   94.20 (-0.78%)
AMZN   89.77 (+1.48%)
TSLA   172.03 (-1.15%)
NVDA   168.84 (+4.74%)
NIO   13.37 (+6.28%)
BABA   94.11 (+6.54%)
AMD   69.76 (-0.54%)
T   19.19 (-0.57%)
MU   55.24 (+2.64%)
CGC   3.05 (-5.86%)
F   13.11 (+0.08%)
GE   83.38 (-1.91%)
DIS   92.51 (+0.39%)
AMC   6.12 (+1.16%)
PYPL   74.44 (+0.03%)
PFE   51.66 (+2.83%)
NFLX   308.73 (+0.10%)
S&P 500   3,954.71 (+0.53%)
DOW   33,699.14 (+0.30%)
QQQ   283.31 (+0.99%)
AAPL   142.20 (+0.89%)
MSFT   247.27 (+1.19%)
META   115.55 (+1.42%)
GOOGL   94.20 (-0.78%)
AMZN   89.77 (+1.48%)
TSLA   172.03 (-1.15%)
NVDA   168.84 (+4.74%)
NIO   13.37 (+6.28%)
BABA   94.11 (+6.54%)
AMD   69.76 (-0.54%)
T   19.19 (-0.57%)
MU   55.24 (+2.64%)
CGC   3.05 (-5.86%)
F   13.11 (+0.08%)
GE   83.38 (-1.91%)
DIS   92.51 (+0.39%)
AMC   6.12 (+1.16%)
PYPL   74.44 (+0.03%)
PFE   51.66 (+2.83%)
NFLX   308.73 (+0.10%)
S&P 500   3,954.71 (+0.53%)
DOW   33,699.14 (+0.30%)
QQQ   283.31 (+0.99%)
AAPL   142.20 (+0.89%)
MSFT   247.27 (+1.19%)
META   115.55 (+1.42%)
GOOGL   94.20 (-0.78%)
AMZN   89.77 (+1.48%)
TSLA   172.03 (-1.15%)
NVDA   168.84 (+4.74%)
NIO   13.37 (+6.28%)
BABA   94.11 (+6.54%)
AMD   69.76 (-0.54%)
T   19.19 (-0.57%)
MU   55.24 (+2.64%)
CGC   3.05 (-5.86%)
F   13.11 (+0.08%)
GE   83.38 (-1.91%)
DIS   92.51 (+0.39%)
AMC   6.12 (+1.16%)
PYPL   74.44 (+0.03%)
PFE   51.66 (+2.83%)
NFLX   308.73 (+0.10%)
NASDAQ:XBIT

XBiotech - XBIT Stock Forecast, Price & News

$3.25
+0.10 (+3.17%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.15
$3.32
50-Day Range
$3.05
$3.79
52-Week Range
$3.00
$12.64
Volume
95,763 shs
Average Volume
35,358 shs
Market Capitalization
$98.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
XBIT stock logo

About XBiotech (NASDAQ:XBIT) Stock

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Receive XBIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter.

XBIT Stock News Headlines

Short Interest in XBiotech Inc. (NASDAQ:XBIT) Expands By 24.7%
XBiotech (NASDAQ:XBIT) Research Coverage Started at StockNews.com
XBiotech Inks Clinical Manufacturing Deal - GlobeNewswire
See More Headlines
Receive XBIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter.

XBIT Company Calendar

Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/08/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XBIT
Employees
97
Year Founded
N/A

Profitability

Net Income
$-17,410,000.00
Net Margins
-440.49%
Pretax Margin
-470.52%

Debt

Sales & Book Value

Annual Sales
$18.39 million
Book Value
$8.86 per share

Miscellaneous

Free Float
21,977,000
Market Cap
$98.93 million
Optionable
Optionable
Beta
1.21

Key Executives

  • Mr. John  SimardMr. John Simard (Age 60)
    Founder, Pres, CEO & Chairman
    Comp: $7.79M
  • Ms. Queena Han B.A. (Age 55)
    C.G.A., CPA, CPA, VP of Fin. & HR and Sec.
    Comp: $489.89k
  • Dr. Sushma Shivaswamy Ph.D. (Age 44)
    Chief Scientific Officer
    Comp: $568.74k
  • Mr. Benjamín Guzmán (Age 66)
    Sr. VP of Corp. Strategy & Fin.
  • Ms. Lisa Simard
    Director of Corp. Strategy - XBiotech USA, Inc.













XBIT Stock - Frequently Asked Questions

How have XBIT shares performed in 2022?

XBiotech's stock was trading at $11.13 at the beginning of the year. Since then, XBIT stock has decreased by 70.8% and is now trading at $3.25.
View the best growth stocks for 2022 here
.

Are investors shorting XBiotech?

XBiotech saw a increase in short interest in November. As of November 15th, there was short interest totaling 119,800 shares, an increase of 24.7% from the October 31st total of 96,100 shares. Based on an average trading volume of 39,800 shares, the days-to-cover ratio is presently 3.0 days. Approximately 0.8% of the company's stock are short sold.
View XBiotech's Short Interest
.

When is XBiotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our XBIT earnings forecast
.

What is John Simard's approval rating as XBiotech's CEO?

20 employees have rated XBiotech Chief Executive Officer John Simard on Glassdoor.com. John Simard has an approval rating of 58% among the company's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of XBiotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Block (SQ).

When did XBiotech IPO?

(XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

Who are XBiotech's major shareholders?

XBiotech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Credit Suisse AG (0.87%), BlackRock Inc. (0.85%), Renaissance Technologies LLC (0.51%), Dimensional Fund Advisors LP (0.28%), Two Sigma Investments LP (0.25%) and Two Sigma Advisers LP (0.23%). Insiders that own company stock include John Simard, Queena Han, Street Financial SA Bay, Sushma Shivaswamy and W Thorpe Mckenzie.
View institutional ownership trends
.

How do I buy shares of XBiotech?

Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $3.25.

How much money does XBiotech make?

XBiotech (NASDAQ:XBIT) has a market capitalization of $98.93 million and generates $18.39 million in revenue each year.

How can I contact XBiotech?

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The official website for the company is www.xbiotech.com. The biopharmaceutical company can be reached via phone at (512) 386-2900, via email at swhitehurst@xbiotech.com, or via fax at 512-386-5505.

This page (NASDAQ:XBIT) was last updated on 12/8/2022 by MarketBeat.com Staff